Latest news with #moleculardiagnostics
Zawya
4 days ago
- Business
- Zawya
Gulf Scientific Corporation announces strategic partnership with GeneMind Biosciences
DUBAI, United Arab Emirates: Gulf Scientific Corporation (GSC), a leading provider of scientific and laboratory solutions, is pleased to announce a strategic partnership with GeneMind Biosciences, a pioneering developer of DNA sequencing systems. This alliance marks a significant milestone in our ongoing commitment to delivering innovative healthcare solutions and advancing molecular diagnostics. Founded with a focus on research and development, GeneMind Biosciences is a key player in the development of high-performance DNA sequencers - core instruments of modern molecular diagnostics. The company is committed to building a comprehensive precision medical ecosystem by collaborating with genetic testing service providers and medical institutions worldwide. This partnership with GSC represents a shared vision to enhance diagnostic capabilities, support cutting-edge scientific research, and ultimately improve patient outcomes. By combining GSC's extensive network and expertise with GeneMind's innovative sequencing technology, we aim to drive forward the future of healthcare through advanced molecular diagnostics, including non-invasive prenatal testing (NIPT). GSC is proud to represent GeneMind Biosciences in the UAE, Kuwait, Oman, Bahrain, and Qatar, bringing their groundbreaking NIPT technology to healthcare providers and patients across these markets. GeneMind's cutting-edge NIPT technology allows for early and accurate detection of fetal chromosomal abnormalities, reducing the risk of miscarriage and improving pregnancy outcomes. This technology has the potential to revolutionize prenatal care and improve the lives of expectant mothers. "We are excited to collaborate with GeneMind Biosciences, whose innovative DNA sequencing solutions align perfectly with our mission to empower healthcare providers to achieve their scientific objectives by providing innovative and reliable solutions, application support, and comprehensive after-sales services," stated Manaf Afyouni, Managing Director of Gulf Scientific Corporation. "Our partnership will enable us to bring cutting-edge NIPT technology to the region, enhancing prenatal care and improving patient outcomes." As part of this strategic partnership, GSC will be providing comprehensive support and services to healthcare professionals within the region. This collaboration will also facilitate the development of new research initiatives and projects focused on advancing molecular diagnostics and NIPT. We look forward to sharing updates on the groundbreaking initiatives and projects that will result from this strategic partnership. For more information about Gulf Scientific Corporation and our solutions, including GeneMind's NIPT technology, please visit Source: AETOSWire Contact details: Manaf Afyouni Email: marketing@ Website:
Yahoo
4 days ago
- Business
- Yahoo
SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30
STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed a collaboration and license agreement with Castle Biosciences (NASDAQ: CSTL), a US-based leader in molecular diagnostics. The initial goal of the collaboration is to develop a test that predicts flares in patients diagnosed with atopic dermatitis (AD). The method will be based on SciBase's EIS technology and specifically, Nevisense, inclusive of both the desktop and point-of care devices. In connection with the collaboration and license agreement, SciBase intends to carry out a directed share issue of approximately SEK 30 million, of which Castle Biosciences has undertaken to subscribe for shares corresponding to a total amount of approximately SEK 19 million. The subscription price in the directed share issue corresponds to SEK 0.40 per share. Additional information regarding the directed share issue will be announced through a separate press release in connection with this press release. Under the collaboration and license agreement, the Companies will jointly explore and develop various clinical indications related to dermatologic diseases. SciBase's initial territory will be the EU, Switzerland, United Arab Emirates, Japan and South Korea, while Castle Biosciences' initial territory will be North America. Assuming development success, SciBase will receive a single-digit royalty percentage on the Castle gross margin as well as a low double-digit percentage mark-up on product sales to Castle. SciBase will also receive a milestone payment of 5 million U.S. dollars when Castle sales reach 50 million U.S. dollars annually. While the development agreement calls for sharing of development costs, SciBase will be deferring its clinical development costs for the initial indication of pre-symptomatically predicting flares in patients diagnosed with atopic dermatitis, with reimbursement being made from future royalty and milestone payments. "This collaboration with Castle Biosciences is exciting for SciBase," said Pia Renaudin, CEO of SciBase. "It will accelerate the use of Nevisense within the skin barrier health market. It will rapidly broaden our already existing clinical studies pipeline by increasing the number of studies, ultimately speeding up access to more effective therapies for patients with skin barrier dysfunction. We are also pleased to welcome Castle as a shareholder in SciBase." "We are excited to expand our commitment to the dermatologic community, clinicians and patients alike, with the signing of this agreement," said Derek Maetzold, CEO of Castle Biosciences. "Atopic dermatitis is a disease that impacts a significant number of lives, worldwide. We are excited about this opportunity to work with SciBase to develop a test that could improve the management of patients diagnosed with this disease, and potentially other dermatologic diseases. We believe this is a good fit for us, with our existing commercial portfolio of tests in skin cancers, as well as our pipeline test in development for use in patients diagnosed with moderate-to-severe AD who are seeking systemic treatment - the majority of which are managed by the same dermatological clinician." In connection with the collaboration and license agreement, SciBase intends to carry out a directed share issue of approximately SEK 30 million. The subscription price in the directed share issue corresponds to SEK 0.40 per share. Castle Biosciences has undertaken to subscribe for 47,886,950 shares in the directed share issue, corresponding to approximately SEK 19 million. Through the directed share issue, Castle Biosciences is becoming one of SciBase's largest shareholders. Additional information regarding the directed share issue will be announced through a separate press release in connection with this press release and will be available at: About Skin Barrier Dysfunction Skin barrier dysfunction is a key contributing factor to a wide range of skin disorders - including atopic dermatitis, psoriasis, ichthyosis, rosacea, and even acne. Estimates suggest that over 500 million people globally are affected by conditions in which skin barrier impairment plays a central role. Estimated global prevalence by condition includes: Atopic dermatitis (eczema): ~223 million1) Psoriasis: ~125 million2) Rosacea: ~400 million (many with impaired barrier function)3) Additionally, a wide range of cosmetic and subclinical skin concerns-such as dryness, irritation, and product sensitivity-are linked to mild or temporary skin barrier disruption. These milder forms may affect over a billion people globally at some point in their lives. This information is information that SciBase Holding AB is obliged to make public pursuantto the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 22.30 CEST on June 16, 2025. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. For further information please contact: Pia Renaudin, CEO,Phone. +46732069802E-mail: Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ)Tel: +46 (0)73 856 42 65E-mail: certifiedadviser@ About SciBase and NevisenseSciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at For press releases and financial reports visit: -------------------------------------------------------------------------------------- 1Global Report on Atopic Dermatitis - 2https:// 3https:// This information was brought to you by Cision The following files are available for download: SciBase PR - collaboration - final Nevisense Go Nevisense new software 2025 with curve EU View original content:
Globe and Mail
09-06-2025
- Business
- Globe and Mail
Molecular Infectious Disease Testing: A Strategic Imperative in the Next Era of Diagnostic Innovation
"Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany)" The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. In a world increasingly shaped by precision medicine and real-time response to public health threats, Molecular Infectious Disease Testing has emerged as a critical force driving both clinical excellence and strategic business transformation. As healthcare systems, diagnostic developers, and life sciences firms recalibrate in the wake of global disruptions, this once-specialized segment now anchors a new paradigm of proactive, data-driven, and resilient healthcare. The Molecular Infectious Disease Testing Market is poised for significant expansion—powered by evolving pathogen landscapes, digital diagnostics, and next-gen sample-to-answer platforms. For C-suite leaders, this moment presents a rare convergence of public health necessity, commercial scalability, and long-term strategic advantage. Download PDF Brochure: Reframing Diagnostics: From Passive Detection to Intelligent Surveillance Historically, infectious disease diagnostics operated as reactive tools—used to confirm a clinical suspicion. Today, molecular testing reframes this narrative. It offers early detection, predictive analytics, and pathogen-level precision across clinical, commercial, and community settings. From hospital labs to point-of-care environments, molecular diagnostics enable providers to shift from treatment to prevention, aligning with global healthcare imperatives. Molecular platforms—driven by PCR, isothermal amplification, and CRISPR-based innovations—now deliver results in under an hour with laboratory-grade accuracy. This speed-accuracy fusion is not merely a clinical upgrade; it fundamentally redefines operational models for diagnostic providers, healthcare systems, and public health authorities. For enterprises invested in diagnostics, the value proposition is clear: real-time infectious disease visibility fuels smarter resource allocation, reduces hospital burden, and enhances patient outcomes, all while positioning stakeholders as architects of the next diagnostic frontier. Strategic Growth Catalysts: What's Driving Market Acceleration Several macro and micro factors coalesce to propel the Molecular Infectious Disease Testing Market into its next growth phase: 1. Expanding Disease Burden and Antimicrobial Resistance (AMR) The global burden of infectious diseases remains persistent, with resurging pathogens (e.g., RSV, TB, dengue) and emerging zoonotic threats challenging static diagnostic infrastructure. Molecular tools provide the agility and specificity needed to differentiate bacterial from viral infections, a critical step in curbing unnecessary antibiotic use and mitigating AMR. 2. Decentralization of Diagnostics The COVID-19 era taught healthcare an invaluable lesson: decentralization saves lives. With the rise of near-patient and at-home molecular testing platforms, diagnostics are no longer tethered to centralized labs. Enterprises that adapt their go-to-market strategies to support distributed testing architectures —via partnerships with retail clinics, mobile labs, or remote monitoring—will unlock new access points and patient touchpoints. 3. Integration with Digital Health and AI AI and machine learning now bolster molecular diagnostics by enhancing pathogen detection accuracy, analyzing multi-pathogen panels, and predicting outbreak trajectories. Diagnostic systems integrated with EHRs and cloud platforms empower real-time clinical decisions, operational benchmarking, and population-level insights. This digital-molecular fusion presents fertile ground for healthcare innovation. 4. Policy and Funding Momentum Across North America, Europe, and APAC, health authorities are expanding reimbursement codes, issuing preparedness grants, and incentivizing rapid diagnostics in low-resource and high-risk settings. This public-private alignment creates a robust financial scaffold that enables enterprise-level scaling of molecular platforms. Real-World Applications: Impact Across Ecosystems Molecular infectious disease testing is already reshaping operations in high-stakes environments: - Hospitals and Health Systems Rapid syndromic panels reduce patient length of stay, enhance cohorting strategies, and improve antimicrobial stewardship. Molecular diagnostics empower ID specialists to tailor therapy within hours, leading to better outcomes and lower costs per diagnosis. - Pharmaceutical R&D Clinical trial timelines for anti-infectives depend on early, accurate identification of pathogens. Molecular testing accelerates patient enrollment and pathogen profiling, de-risking development pipelines and expediting time-to-market for novel therapeutics. - Public Health and Biosecurity Central and regional agencies are embedding molecular testing into surveillance systems. These platforms offer real-time outbreak detection and genomic surveillance to preempt community spread, identify variants, and inform containment protocols. - Travel, Defense, and Corporate Health Airports, military bases, and corporate campuses now deploy rapid molecular testing for pre-entry screening and ongoing surveillance. This enables safe continuity of operations in mission-critical sectors. Industry Trends and Long-Term Shifts: Preparing for 2030 The next five years will define the blueprint for molecular diagnostics—shaped by three dominant themes: 1. Platform Convergence The future is not single-pathogen but multiplexed and modular. Next-gen systems will support simultaneous detection of viral, bacterial, and fungal targets on customizable panels—driven by cloud-based upgrades and modular chemistry. 2. Global Accessibility Low- and middle-income countries (LMICs) represent a major growth frontier. Companies investing in affordable, ruggedized, solar-compatible molecular platforms stand to gain first-mover advantage in these underserved yet high-need markets. 3. Consumerization and At-Home Testing With rising health literacy and demand for convenience, molecular diagnostics will continue migrating into consumer channels, supported by e-commerce, telehealth integration, and mobile sample logistics. Strategic partnerships with digital health platforms will be crucial for brand relevance and scale. Business Opportunity Landscape: Where the Growth Lies C-suite leaders, investors, and business strategists eyeing the molecular infectious disease testing space should consider five high-potential opportunity zones: A. Horizontal Expansion into Adjacent Conditions Beyond traditional infectious diseases, molecular platforms are being adapted for oncology (viral-driven cancers), transplant monitoring, and immune dysfunction diagnostics. This expands addressable markets and strengthens platform utility. B. Strategic M&A and Licensing Models Smaller diagnostic innovators with novel amplification chemistries, miniaturized hardware, or AI overlays are ripe for acquisition or joint ventures. Corporates seeking to build comprehensive diagnostic ecosystems must prioritize these integrations. C. Private-Public Lab Collaborations Innovative partnerships between diagnostics firms and health agencies (local, federal, or international) will streamline test deployment in underserved geographies, leveraging pooled resources and shared logistics. D. Outcome-Based Reimbursement Models The shift to value-based care compels diagnostics providers to demonstrate impact on outcomes and cost avoidance. Firms that can link molecular testing to reduced admissions, antibiotic usage, or outbreak costs will command premium reimbursements. E. Supply Chain and Manufacturing Localization Post-pandemic disruptions underscore the value of regionalized manufacturing and agile logistics. Companies investing in decentralized, scalable production will enjoy lower lead times, geopolitical risk insulation, and margin protection. A Call to Action: Redefining the Diagnostic Future The evolution of Molecular Infectious Disease Testing represents more than a technological upgrade—it's a business imperative with the potential to redefine diagnostics, reshape public health response, and reimagine the value chain across healthcare. Senior executives who treat molecular testing as a strategic pillar—not a supplemental tool—will lead the industry's transformation. This moment requires bold investments, long-horizon vision, and operational agility. Whether you are a diagnostic innovator, a health system leader, a policy architect, or a life sciences strategist, the time to act is now. The trajectory is clear: the future of infectious disease testing is molecular, digital, decentralized, and intelligent. Those who move early, scale smartly, and innovate continuously will not only lead markets—they will help safeguard global health. For more information, Inquire Now!
Entrepreneur
07-06-2025
- Business
- Entrepreneur
Biopeak Raises USD 3.5 Million to Expand AI-Driven Health Clinics
"We're at a unique point where developments in molecular diagnostics, AI, and imaging allow us to understand the human body in unprecedented ways," says Rishi Pardal, Co-founder and CEO of Biopeak Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Biopeak, a wellness and longevity-focused startup headquartered in Bengaluru, has raised USD 3.5 million (approximately INR 29 crore) in seed funding from a group of notable investors. The round saw participation from Accel founding partner Prashanth Prakash, Claypond Capital--the family office of Manipal Group chairman Ranjan Pai and NKSquared, the investment arm of Zerodha co-founder Nikhil Kamath. Founded in 2024 by Rishi Pardal and Shiva Subramanian, Biopeak delivers personalised health services through its own clinics, combining advanced diagnostics, molecular science, and artificial intelligence (AI) to monitor early signs of physiological change. The company launched its first clinic in Bengaluru in March 2025. The funding will be used to expand Biopeak's clinic footprint across key Indian cities and strengthen its AI-based diagnostic and care delivery platform. "We're at a unique point where developments in molecular diagnostics, AI, and imaging allow us to understand the human body in unprecedented ways," said Rishi Pardal, Co-founder and CEO of Biopeak. "Our platform translates these insights into actionable, individualised health plans aimed at extending one's healthspan, not just lifespan." Biopeak's approach includes a suite of diagnostic tools such as microbiome mapping, organic acid profiling, salivary cortisol rhythm analysis, and whole-exome functional genomics. These are integrated with non-invasive imaging technologies including MRI, CT, DXA, and ECHO, along with tissue-level screenings to assess toxin levels, mineral balance, and oxidative stress. Clients typically undergo more than six hours of detailed consultations guided by a dedicated health manager and a multidisciplinary team of specialists. Health plans are updated regularly based on follow-up tests and consultations. Commenting on the investment, Prashanth Prakash said, "As India's population ages, our challenge is to build systems that not only extend life but also improve the quality of those extended years. Geroscience, early interventions, and scalable healthcare models will be central to this shift." Prakash, who also mentors Biopeak, is the Founding Patron of Longevity India, a platform focused on ageing research and interventions tailored for India's demographic needs.
Yahoo
20-05-2025
- Health
- Yahoo
North America Infectious Disease Rapid Diagnostics Market Report 2025-2035 Featuring Abbott, F. Hoffmann-La Roche, Danaher, DiaSorin, Hologic, BGI, Quidel, Cellex, bioMerieux, Thermo Fisher Scientific
The North American infectious disease rapid diagnostics market is growing due to rising incidences of diseases like influenza and STIs, driving demand for fast diagnostic tests. Key technologies include molecular diagnostics and antigen tests, crucial for early detection and managing infections. The U.S. leads the market, benefiting from a robust healthcare system and regulatory support. Challenges include strict FDA regulations and high costs. Major players like Abbott and Thermo Fisher are innovating to meet rising demands for effective, rapid diagnostics. Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "North America Infectious Disease Rapid Diagnostics Market - A Regional Analysis: Focus on Product, Technology, Application, and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to Disease Rapid Diagnostics are tests designed to quickly detect and identify infectious agents such as bacteria, viruses, or fungi, enabling fast treatment decisions. These tests provide results in minutes to a few hours, crucial for early detection and effective management of infections. They include molecular diagnostics, antigen tests, and serological assays for diseases such as influenza, COVID-19, and increasing incidence of infectious diseases such as influenza, sexually transmitted infections (STIs), respiratory infections, and hospital-acquired infections (HAIs) is a major driver of the North American rapid diagnostics market. For instance, the CDC reported in 2023 that the U.S. experienced an uptick in flu cases, with over 15 million cases reported that year, emphasizing the need for fast and efficient diagnostic tests. The growing threat of antimicrobial resistance (AMR) and the emergence of novel pathogens, such as the resurgence of multidrug-resistant tuberculosis and the rise of drug-resistant gonorrhea, have made early and accurate disease detection more critical than ever to control outbreaks and prevent further governments and healthcare organizations are heavily investing in rapid testing solutions to enhance early disease detection and control outbreaks. During the 2023 influenza season, the U.S. government expanded the use of Quidel's Sofia 2 SARS Antigen FIA test for quick identification of flu and COVID-19 co-infections in emergency departments. The demand for point-of-care (POC) diagnostics in emergency settings, outpatient clinics, and remote locations has risen as healthcare systems strive to reduce diagnostic turnaround times and improve patient outcomes. For instance, the Abbott ID NOW molecular diagnostic system has been deployed widely in rural and remote areas to quickly detect respiratory infections such as flu and COVID-19, providing results in just 15 minutes.A significant opportunity in the North American rapid diagnostics market lies in the expansion of point-of-care testing (POCT) across decentralized healthcare settings, such as pharmacies, urgent care centers, and home-based testing. The rising demand for fast, reliable, and affordable diagnostics outside of traditional hospital environments is opening new growth avenues for diagnostic companies. With growing government support and increasing regulatory approvals for POCT, the adoption of portable diagnostic devices is expected to surge, particularly for diseases like STIs, respiratory infections, and gastrointestinal the major challenges faced by the North America infectious disease rapid diagnostics market are the stringent regulatory framework and pricing constraints. The FDA approval process for new diagnostic tests can be time-consuming and complex, delaying product launches and market entry. For instance, Cepheid's Xpert Xpress COVID-19 test, while highly effective, faced regulatory hurdles and delays before it received Emergency Use Authorization (EUA) in 2020. The approval process for new technologies can extend product launch timelines, delaying access to critical the high cost of advanced molecular diagnostic technologies such as q-PCR and INAAT makes them less accessible, particularly in resource-limited settings. Although reimbursement policies are improving, inconsistent insurance coverage for rapid diagnostic tests remains a barrier to widespread adoption. A study published by the National Institutes of Health (NIH) found that the cost of a single qPCR test for COVID-19 could range from $100 to $200, limiting accessibility in smaller clinics or remote healthcare pressures also arise due to competition from generic or low-cost diagnostic alternatives, especially in non-hospital settings. Moreover, healthcare providers are often hesitant to adopt new diagnostic technologies without clear cost-effectiveness data or strong clinical validation. These regulatory and pricing challenges could slow market growth and limit accessibility to cutting-edge diagnostic market players in the North American infectious disease rapid diagnostics market are focusing on innovation, strategic partnerships, and expanding product offerings to meet the growing demand for faster, more accurate testing solutions. For instance, in April 2022, Thermo Fisher Scientific, Inc. launched the TaqPath COVID-19 RNase P 2.0 Assay Kit, designed to detect SARS-CoV-2, including emerging players in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, DiaSorin S.p.A, Hologic, Inc., BGI Group,Quidel Corporation, Cellex,bioMerieux S.A., and Thermo Fisher Scientific Inc., etc. Assay to Lead the Infectious Disease Rapid Diagnostics MarketAssays dominate the North America infectious disease rapid diagnostics market due to their widespread applicability, affordability, and efficiency in detecting a range of infectious diseases. Assays, including immunoassays and molecular assays, are used extensively in hospitals, clinics, and point-of-care (POC) settings for rapid disease detection, enabling timely treatment decisions. Their cost-effectiveness compared to fully automated diagnostic systems makes them accessible to a broader range of healthcare the rising prevalence of infectious diseases such as respiratory infections, sexually transmitted infections (STIs), and gastrointestinal infections, demand for rapid and accurate diagnostic assays is increasing. Advances in multiplex assays, capable of detecting multiple pathogens from a single sample, further enhance their clinical value. Additionally, regulatory approvals for at-home diagnostic assays, particularly for diseases like COVID-19 and influenza, are expected to drive market expansion. As a result, assays remain a cornerstone of infectious disease diagnostics. Real-Time Polymerase Chain Reaction (q-PCR) to Lead the Infectious Disease Rapid Diagnostics MarketReal-Time Polymerase Chain Reaction (q-PCR) is projected to be the dominant technology in the North America infectious disease rapid diagnostics market due to its high sensitivity, specificity, and rapid turnaround time. q-PCR is widely used for detecting viral and bacterial infections, particularly in hospital laboratories and reference labs where accuracy is crucial for clinical key advantage of q-PCR is its ability to quantify pathogen load, enabling physicians to monitor disease progression and treatment effectiveness. The increasing incidence of respiratory infections (e.g., COVID-19, influenza, RSV) has led to widespread adoption of q-PCR tests. Moreover, innovations in portable and automated q-PCR devices are expanding the technology's usability in point-of-care (POC) and decentralized ongoing advancements in multiplex PCR assays, which allow simultaneous detection of multiple pathogens, q-PCR will continue to be the gold standard for rapid, high-accuracy infectious disease diagnostics.U.S. Region to Lead the North America Infectious Disease Rapid Diagnostics Market (by Country)The U.S. is expected to lead the North America infectious disease rapid diagnostics market throughout the forecast period due to several key factors. The country has a high prevalence of infectious diseases, such as respiratory, gastrointestinal, and sexually transmitted infections, which drives the demand for rapid diagnostic solutions. The U.S. also boasts a robust healthcare infrastructure with well-established hospitals, diagnostic centers, and research institutions that promote the adoption of innovative diagnostic technologies. Regulatory support from the FDA, including expedited approval pathways, allows faster market entry for new diagnostic products, further fueling growth. Additionally, increased investments from government initiatives, private sector funding, and collaborations between biotech companies and academic institutions are boosting R&D in rapid diagnostics. The U.S. remains at the forefront of adopting advanced diagnostic technologies, including molecular diagnostic platforms, AI-driven tools, and portable rapid test kits. While Canada experiences steady growth, the U.S. will continue to be the primary driver of market expansion in the region. Key Topics Covered:1. Markets: Industry Outlook1.1 Trends: Current and Future Impact Assessment1.2 R&D Review1.2.1 Patent Filing Trend by Year1.3 Regulatory Landscape1.4 Market Dynamics1.4.1 Market Drivers1.4.2 Market Restraints1.4.3 Market Opportunities2. North America Infectious Disease Rapid Diagnostic Market (by Product)2.1 Assays2.2 Platforms3. North America Infectious Disease Rapid Diagnostic Market (by Technology)3.1 Real-Time PCR (q-PCR)3.2 Isothermal Nucleic Acid Amplification Technology (INAAT)3.3 Others4. North America Infectious Disease Rapid Diagnostic Market (by Application)4.1 Respiratory Infection4.2 Gastro-Intestinal Infection4.3 Hospital Acquired Infection4.4 Sexually Transmitted Infections4.5 Others5. North America Infectious Disease Rapid Diagnostic Market (by Country)5.1 U.S5.2 Canada6. Competitive Landscape and Company Profiles 6.1 Key Strategies and Developments6.1.1 Product Approvals6.1.2 Product Launches and Upgradations6.1.3 Synergistic Activities6.1.4 Funding and Expansion6.1.5 Mergers and Acquisitions6.2 Company Profiles6.2.1 Company Overview6.2.2 Product Portfolio6.2.3 Top Competitors6.2.4 Analyst View Abbott Laboratories F. Hoffmann-La Roche Ltd Danaher Corporation DiaSorin S.p.A Hologic, Inc. BGI Group Quidel Corporation Cellex bioMerieux S.A. Thermo Fisher Scientific Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
